gsk201410146k2.htm
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending October 2014
 
GlaxoSmithKline plc
(Name of registrant)


 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.


 
 
Yes      No x
--


 

 
Notification of Transactions of Directors, Persons Discharging
Managerial Responsibility or Connected Persons
 
 
The Administrators of the GlaxoSmithKline 2009 Performance Share Plan (the Plan) notified the Company and the under-mentioned Directors and Persons Discharging Managerial Responsibility (PDMR) on 14 October 2014 of the following increases in their notional interests in Ordinary Shares at a price of 1404.00 pence per Ordinary Share and American Depositary Shares (ADSs) at a price of $45.63 per ADS following the notional re-investment of the dividend paid to shareholders on 2 October 2014.
 
 
Director/PDMR
Ordinary Shares
ADSs
Sir Andrew Witty
18,700.225
 
Dr M M Slaoui
 
5,761.611
Mr S Dingemans
7,854.435
 
Mr R G Connor
2,568.688
 
Mrs D P Connelly
 
2,395.995
Mr J Ford
 
309.896
Mr S A Hussain
6,371.575
 
Mr W C Louv
 
1,690.149
Mr D S Redfern
2,704.765
 
Ms C Thomas
3,732.993
 
Mr P C Thomson
1,820.901
 
Mr D E Troy
 
3,424.225
Dr P J T Vallance
7,777.092
 
Ms E Walmsley
4,520.938
 
Mrs V A Whyte
517.597
 
 
 
 
The notional dividends accrued will be paid out in proportion to the percentage of participants' Plan holdings that vest following the end of the relevant measurement period.
 
This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
 
 
V A Whyte
Company Secretary
 
14 October 2014


 
 
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.



 
 
GlaxoSmithKline plc
(Registrant)


Date: October 14, 2014 
 
 
By: VICTORIA WHYTE
----------------------
 
 
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc